All Stories

  1. Aging People with Viral Infection, Novel Strategies
  2. Bone Tumor Metastasis Therapeutics, New Ideas and Perspectives
  3. COVID 19 Study, Drug Selection and Development
  4. Anticancer Drug Combinations: Different Strategies Used in the Clinic
  5. Cancer Bioinformatics, New Chapter of Personalized Medicine
  6. Suicide study, past progress and diagnostic transition
  7. Pulmonary nodules, knowledge renovation and comprehensive studies
  8. Personalized Oncology: Scientific and Technical Approaches
  9. Advances in Cancer Therapeutics and Genomics for Improved Patient Outcomes
  10. Magnetic water and clinical cancer chemotherapy
  11. Nursery Services in Future
  12. Human suicide, clinical treatment overview
  13. Sexually transmitted disease diagnosis and treatments, risk factors from beyond
  14. Human suicide, risk factors and new perspective
  15. Suicide study, new approaches
  16. Human suicide, molecular framework
  17. COVID-19 knowledge and therapeutics, past, present and future
  18. Artificial intelligence for advancing nursery service
  19. Treatment improvements by pediatric Theranostics
  20. COVID-19 conception advances, epidemics, pathology and therapeutics
  21. Withdrawn: Professor Bin Xu, A Legendary Pharmacologist in People’s Republic of China
  22. Sialic Acids and Cancer: Pathophysiological Association between Metastatic Progress and Treatment
  23. Anticancer Drug Development, Pharmaceutical Progress
  24. Human Suicide, Biomedical Knowledge Advances
  25. Type 2 Diabetes Treatments in Countries of Different Economic Status
  26. Human suicide, biomedical knowledge and therapeutic advances
  27. Human Suicide, an Overview of Management Strategies
  28. COVID-19 Research, Public Health and Biomedical Basis
  29. Human Suicide, Management Landscape
  30. Anticancer Drug Development: Evaluative Architecture
  31. COVID-19 Study: A New Principle Discovery
  32. COVID-19 Study, Diagnostic and Therapeutic Transition
  33. Antimetastatic Drug, Pharmacologic Challenge and Opportunity
  34. Nursery services advances, global campaign
  35. Different approaches to bone transplantation surgery
  36. Bone Metastasis Diagnosis, Blood Biomarker Detections
  37. Anti-metastatic drug development, overview and perspectives
  38. Educational Perspectives for Nursery
  39. Is Tau Molecule Regarded as a Risk Factor for Human Suicide?
  40. Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
  41. Suicide Curative Treatment Study and Drug Development
  42. Pulmonary nodules, is there any pathogenesis evidence?
  43. HIV/AIDS Curability Study, Different Approaches and Drug Combination
  44. Pulmonary nodules, surgery or other medication
  45. Bone Metastasis and Circulation Biomarkers Profiling Towards Personalized Cancer Medicine
  46. Pulmonary Nodules, Surgery or Other Medication
  47. Anti-Metastatic Drug Developments, Utility of More Animal Models
  48. Several approaches for anticancer drug development progress
  49. Drug Sensitivity Testing for Cancer Therapy, Key Areas
  50. COVID-19 infection for metabolic abnormal human beings
  51. Fundamental knowledge for nurses 
  52. Nursery promotion, education and system updating
  53. Cancer Bone Metastasis, Diagnostic Insights and Drug Selection
  54. Covid-19 Study, Pathology and Therapeutics
  55. Acupuncture for Bone Disease Treatments, Modern Approaches
  56. Cancer Bone Metastasis, Experimental Study
  57. Neuropsychiatric Approaches for Human Suicide Prediction and Management
  58. Osteoporosis Targeting, Possible Breakthroughs
  59. Neuropsychiatric insights for human suicide
  60. Bone Cancer and Metastasis Trials, Drug Treatment
  61. Neurobiology for human suicide
  62. Bone Disease Treatment Study, Major Pathways
  63. Pathology Study for Human Suicide
  64. Nursery activity and quality, chemistry between doctors and nurses
  65. Nursery education, narrow-range or wide-range
  66. Anticancer drug development, challenge and dilemma
  67. Life Origin on Earth, Knowledge Development
  68. HIV/AIDS treatment, therapeutic strategy break throughs
  69. Nursery education for diabetes
  70. Suicide Risks and Prevention, Neuropathogenic Study
  71. Medical Treatments for Chronic or Aggressive Diseases, Palliative Therapy and Nursery
  72. General information for nursery
  73. Historical analysis of suicide
  74. Drug sensitivity testing, a unique drug selection strategy
  75. Natural drug cancer treatments, strategies from herbal medicine to chemical or biological drugs
  76. Medical treatments for incurable diseases, palliative therapy
  77. Life Origin on Earth, Biochemical Approaches
  78. Nursery training, from technique details in schools into medical knowledge education in nursery career
  79. Herbal medicine in new era
  80. Nursery service, quality promotion
  81. Anti-Metastatic Drug Developments, Biomedical Mechanisms and Therapeutic Categorization
  82. RETRACTED: Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate
  83. Patient’s care and nursery in different diseases
  84. Ebola Therapeutic Study and Future Directions
  85. New HIV/AIDS Therapeutics
  86. Nursery Service in Modern Days
  87. Nursery Education, Capability and Service Promotion
  88. Nursery Science and Conventions
  89. Cancer Bioinformatics in Cancer Therapy
  90. Individualized Cancer Therapy
  91. Human Suicide Risk and Treatment Study
  92. Type 2 Diabetes Treatment and Drug Development Study
  93. Hypotheses for Life Origin on Earth, Comparison and Validation
  94. Type 2 Diabetes Study, Introduction and Perspective
  95. Type 2 Diabetes Mellitus Study, A Process of Enigma unraveling
  96. Anthocyanins and its biological & therapeutic characters
  97. Diabetes Prevention and Treatments, a Specific Topic for Modern Medicines
  98. A Critical Appraisal of Different Food Safety and Quality Management Tools to Accomplish Food Safety
  99. Pathology and treatments of obesity
  100. Obesity, Risks and Managements
  101. Keep up the pace of drug development evolution and expenditure
  102. An Overview of Obesity
  103. General Topics in the Field of Personalized Cancer Therapy
  104. Human Suicide Risk Study and Treatment: A Mathematical Approach
  105. Anti-Metastatic Drug Developments: Work Out towards New Direction
  106. Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
  107. Drug Combination in Clinical Cancer Treatments
  108. General outlook for individualized cancer therapy
  109. Ebola origin and treatment
  110. Different Disciplines in the Field of Suicide Study
  111. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
  112. HAART in HIV/AIDS Treatments
  113. Anticancer Drug Development, System Updating and Global Participations
  114. Life Origin on Earth, What is the Right Answer?
  115. Life Origin on Earth, What is the Right Answer?
  116. Anticancer Drug Development, Getting out from Bottleneck
  117. Anticancer Drug Development, Getting out from Bottleneck
  118. Human suicide study, major disciplines and treatment outcomes
  119. Anticancer drug development
  120. HIV in Human Genomes and Therapeutics
  121. HIV Biotherapy and Natural Chemotherapeutic Agents
  122. Anticancer Drug Combinations, How Far We can Go Through?
  123. Antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot
  124. Life Origin on Earth, Insights among Different Arguments
  125. Genetics in Suicide Treatments, Modern Diagnosis Establishments
  126. Diabetes Preventions and Treatments, a Specific Topic for Modern Medicines
  127. Anticancer Drug Development, Breakthroughs are Waiting
  128. Cancer metastasis treatment, a key drawbacks
  129. The suicide treatment, a new model
  130. HIV Vaccine for Prevention and Cure, A Mission Possible
  131. Zika Therapy
  132. HIV vaccine
  133. Discover Natural Chemical Drugs in Modern Medicines
  134. Mathematics in biomedical science
  135. The origin of HIV
  136. Human suicide study
  137. Mathematics or Physics-Majored Students on the Biomedical Fields, Insiders or Outsiders?
  138. The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments
  139. Pharmacogenetics of Cancer Therapy
  140. Anticancer Drug Sensitivity Testing
  141. New Perspectives of HIV/AIDS Therapy Study
  142. Antidepressant treatment study
  143. Clinical neoplasm metastasis treatments according to patient's personal conditions.
  144. Assistant cancer treatments in the clinic
  145. Drug sensitivity testing in clinical cancer treatments
  146. Anticancer drug combination in the clinic
  147. Anticancer drug pharmacogenomics in cancer chemotherapy
  148. Cost-effectiveness for personalized cancer therapy
  149. Conclusion
  150. Introduction
  151. Discussion
  152. Cancer biomarker/bioinformatics detection in clinical cancer treatments
  153. Anti-diabetic treatments
  154. Anticancer Drug Combinational Study
  155. The Origins of HIV
  156. Plasma Fibrinogen Concentrations in Patients with Solid Tumors and Therapeutic Improvements by Combining Anticoagulants or Fibrinolytical Agents
  157. Anticancer Drug Combinations, A Big Momentum is Needed
  158. Anticancer Drug Development, a Matter of Money or a Matter of Idea?
  159. Future Perspectives for Controlling Ebola Epidemics
  160. Ebola Origin and Therapies
  161. Cancer Bioinformatics, its Impacts on Cancer Therapy
  162. Copyright
  163. List of figures and tables
  164. Anti-diabetic treatments, patho-therapeutic relation
  165. Origin of Ebola, hypothesis
  166. Personalized Cancer Therapy: A Perspective
  167. Rethink Of Diabetes Treatment and Drug Development
  168. Pharmacogenomics in human suicide prediction and treatments
  169. Cancer metastasis treatment study and drug developments
  170. Challenge for HIV/AIDS therapy
  171. Cost-effectiveness Considerations of Individualized Cancer Chemotherapy
  172. Drug Combinations in Cancer Treatments
  173. New Insights into Individualized Antimetastatic Therapy
  174. Anticancer drugs on serum sialic acid level in mice bearing LLC
  175. Drug Combinations in Cancer Treatments
  176. Genetics in Neural Toxicity of Drugs
  177. Avian flu, pathogenesis and therapeutic study
  178. First Genetic Information Replication in Life Origin on Earth
  179. Origins of Life, A New Cooperative Model
  180. Cancer Metastases and Clinical Therapies
  181. Origins of Life, RNA world or alternative RNA world
  182. Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids
  183. Individualized Cancer Chemotherapy by Detecting Cancer Biomarkers
  184. Antimetastatic Therapies according to Metastatic Cascade
  185. Genetics in antidepressant-induced suicide
  186. Pathology of Drug-induced mania & suicide
  187. Influenza treatment
  188. High Active Anti-retroviral Therapy for HIV/AIDS, Progresses and Drawback
  189. Individualized cancer chemotherapy
  190. High Active Antiretroviral Therapy for HIV/AIDS-Early Intervention or Later Intervention?
  191. The Hypotheses for the Pathogeny of Drug-Induced Mania and Suicide
  192. The Relationship between Tumor Sialic Acids and Neoplasm Metastasis and as a Drug Target
  193. Genomic study of antidepressant-induced suicide
  194. Aberrant sialylation in tumor cells
  195. Anti-mobility of Bisdioxopiperanes against human mammary tumors
  196. Antimetastatic activity and mechanisms of action of Bisdioxopiperazine compounds
  197. Neural toxicity of drugs
  198. Anticancer activity and mechanisms of Bisdioxopiperazines
  199. Different Spontaneous Pulmonary Metastasis Inhibitions against Lewis Lung Carcinoma in Mice by Bisdioxopiperazine Compounds of Different Treatment Schedules
  200. 14C-probimane in the mice bearing LLC
  201. Unsatisfactory design of human AIDS genome research
  202. Antidepressant in Cancer Treatment
  203. AIDS and human genome studies, from a hypothesis to systematic approaches
  204. Antidepressants in Human suicide
  205. Mathematical model in therapeutic risk prediction
  206. Fibrinogen in neoplasm metastasis
  207. Sequencing the whole genome of infected human cells obtained from diseased patients – a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases
  208. Relationship Between Blood Fibrinogen Concentration and Pathological Features of Cancer Patients: A 139-case Clinical Study
  209. Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
  210. Individualized cancer chemotheray
  211. Anti-proliferative and chromosome segregation by probimane and MST-16
  212. Effect of Anti-Cancer Drugs on the Binding of 125I-Fibrinogen to Two Leukaemia Cell Lines In Vitro
  213. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo
  214. Inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes
  215. Aberration of sialylation in neoplasm metastasis and possible therapeutics
  216. Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients
  217. Effect of magnetized water on the mice given high doses of antineoplastic drugs
  218. Inhibition of probimane on lipoperoxidation of human red cells in vitro
  219. Enzyme dynamic study on calmodulin Ca++-Mg++-ATPase system of red blood cells inhibited by α-anordrin and probimane
  220. Journal of Clinical and Medical Reviews